Cover Image

Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Heart Failure: An Update

Diabetes mellitus and heart failure are two diseases that are commonly found together, in particular in older patients. High blood glucose has a detrimental effect on the cardiovascular system, and worse glycemic control contributes to the onset and the recrudesce of heart failure. Therefore, any sp...

Full description

Saved in:

Bibliographic Details
Main Authors:	Nicia I. Profili (Author), Roberto Castelli (Author), Antonio Gidaro (Author), Roberto Manetti (Author), Margherita Maioli (Author), Alessandro P. Delitala (Author)
Format:	Book
Published:	MDPI AG, 2024-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure Management: The Continuing Challenge of Clinical Outcome Endpoints in Heart Failure Trials
by: Luxi Ji, et al.
Published: (2023)

Quantitative effects of sodium-glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients
by: Dong-Dong Wang, et al.
Published: (2022)

The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction
by: Lindsay Brust-Sisti, et al.
Published: (2022)

Inhibitors of sodium-glucose cotransporter 2: risk of ketoacidosis
by: T. M. Bukatina, et al.
Published: (2018)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
by: Jun Tang, et al.
Published: (2022)

Bibliometric and visualized analysis of sodium-Glucose cotransporter 2 inhibitors
by: He Sun, et al.
Published: (2023)

Association Between Use of Sodium-Glucose Cotransporter-2 Inhibitors or Angiotensin Receptor-Neprilysin Inhibitor and the Risk of Atherosclerotic Cardiovascular Disease With Coexisting Diabetes and Heart Failure
by: Ya-Wen Lin PhD, RN, et al.
Published: (2024)

USE OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS BY CARDIOLOGISTS SINCE THE RELEASE OF 2022 AHA/ACC/HFSA GUIDELINES FOR THE MANAGEMENT OF HEART FAILURE
by: Gowtham R. Grandhi, MD MPH, et al.
Published: (2023)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors Use among Heart Failure Patients and the Role of Pharmacists in Early Initiation of Therapy
by: Mohammed Aldhaeefi, et al.
Published: (2023)

Bibliometric Study of Sodium Glucose Cotransporter 2 Inhibitors in Cardiovascular Research
by: Lu Chen, et al.
Published: (2020)

An Overview of the Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Hematological Parameters in Diabetic Patients
by: Ghada Ahmed, et al.
Published: (2023)

Sodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review
by: Thahesh Tharmaraja, et al.
Published: (2022)

Promising role of sodium-glucose cotransporter-2 inhibitors in IgA nephropathy
by: Samaneh Zandifar, et al.
Published: (2023)

Sodium-glucose cotransporter 2 inhibitors: mechanisms of cardiorenal protection: A review
by: Marina V. Leonova
Published: (2024)

Sodium Glucose Cotransporter-2 Inhibitors in Non-Diabetic Kidney Disease: Evidence in Experimental Models
by: Giovanna Castoldi, et al.
Published: (2024)

Sodium-glucose cotransporter-2 inhibitors: A potential novel treatment for Lafora disease?
by: Paola Imbrici, et al.
Published: (2024)

Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects
by: Atsuo Tahara, et al.
Published: (2016)

Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin
by: Sanon VP, et al.
Published: (2017)

Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, anti-diabetic drugs in heart failure and cognitive impairment: potential mechanisms of the protective effects
by: Maria Antonietta Riemma, et al.
Published: (2024)

Sodium-Glucose Cotransporter 2 Inhibitor Use Among Individuals Age <65 with Type 2 Diabetes and Heart Failure with Reduced Ejection Fraction: A Cost–Benefit Analysis
by: Glover S, et al.
Published: (2022)

Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes
by: Navya Varshney, et al.
Published: (2021)

Polypharmacy influences the renal composite outcome in patients treated with sodium‐glucose cotransporter 2 inhibitors
by: Kazuo Kobayashi, et al.
Published: (2022)

Sodium-Glucose Cotransporter 2 Inhibitors Work as a "Regulator" of Autophagic Activity in Overnutrition Diseases
by: Kazuhiko Fukushima, et al.
Published: (2021)

Severe intoxication caused by sodium-glucose cotransporter 2 inhibitor overdose: a case report
by: Miho Nakamura, et al.
Published: (2020)

Sodium glucose co-transporter 2 inhibitors in heart failure therapy
by: Yüksel Çavuşoğlu, et al.
Published: (2020)

Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes
by: Derosa G, et al.
Published: (2018)

Influence of sodium/glucose cotransporter-2 inhibitors on the incidence of acute kidney injury: a meta-analysis
by: Qian Wang, et al.
Published: (2024)

Sodium-glucose cotransporter-2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis
by: Annamaria Mascolo, et al.
Published: (2023)

Quality of methodological reporting of randomized clinical trials of sodium-glucose cotransporter-2 (sglt2) inhibitors
by: Hadeel Alfahmi, et al.
Published: (2017)

Impact of sodium-glucose cotransporter-2 inhibitors on kidney outcomes in type 2 diabetes: A tertiary center experience
by: Mohammed H Tawhari, et al.
Published: (2023)

Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice
by: Atsuo Tahara, et al.
Published: (2016)

Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes
by: Shin Kawasoe, et al.
Published: (2017)

Administration of sodium-glucose cotransporter-2 inhibitors in kidney transplant patients with diabetes: a systematic review and meta-analysis
by: Hamidreza Khodabandeh, et al.
Published: (2023)

Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin
by: Daniel A. Kelmenson MD, et al.
Published: (2017)

A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini Review
by: Jinfang Song, et al.
Published: (2023)

A Potential Mechanism of Cardio-Renal Protection with Sodium-Glucose Cotransporter 2 Inhibitors: Amelioration of Renal Congestion
by: Satoru Kuriyama
Published: (2019)

The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: From molecular mechanisms to potential clinical implications
by: Konstantinos Arvanitakis, et al.
Published: (2022)

Highly selective sodium glucose cotransporter type 2 inhibitor empagliflozin neuroprotective potential in chronic brain dyscirculation
by: Оksana S. Fuks, et al.
Published: (2023)

Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin
by: Min-Koo Choi, et al.
Published: (2020)

In Vitro Metabolism of DWP16001, a Novel Sodium-Glucose Cotransporter 2 Inhibitor, in Human and Animal Hepatocytes
by: Ju-Hyun Kim, et al.
Published: (2020)